BCM
PTLA

Bluefin Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bluefin Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$465K – 587
2019
Q2 		$465K Buy
+100,000
New +$3.14M 0.07% 152

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Bluefin Capital Management's PTLA Position: Q3 2019 in Review

Bluefin Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2019, closing a stake of 61,021 shares — an estimated $1.66M sold.

Bluefin Capital Management first reported a position in PTLA in Q2 2019 and held it in 1 quarter. The position peaked at $1.66M in Q2 2019. 212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

  • Bluefin Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Bluefin Capital Management sold 61,021 Portola Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1.66M.
  • Bluefin Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Bluefin Capital Management's Portola Pharmaceuticals, Inc. position peaked at $1.66M in Q2 2019.
  • 212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on Bluefin Capital Management's 13F filing for Q3 2019, filed 15 Nov 2019.